8-K: CytoDyn Appoints CBIZ as New Independent Auditor Following Marcum LLP's Resignation

CytoDyn Inc. replaces its independent auditor, Marcum LLP, with CBIZ CPAs P.C. after Marcum's attestation business was acquired and Marcum subsequently resigned.

Summary

• CytoDyn Inc. has appointed CBIZ CPAs P.C. as its new independent registered public accounting firm, effective May 14, 2025.
• This change follows the acquisition of Marcum LLP's attest business by CBIZ on November 1, 2024, and Marcum's subsequent resignation on May 14, 2025.
• The Audit Committee of CytoDyn's Board of Directors approved the engagement of CBIZ.
• Marcum's audit report for the fiscal year ended May 31, 2024, included an expression of substantial doubt about CytoDyn's ability to continue as a going concern but did not contain any adverse opinions or disclaimers.
• CytoDyn has confirmed that there were no disagreements with Marcum on accounting principles, practices, financial statement disclosure, or auditing scope during the fiscal year ended May 31, 2024, and the subsequent interim period through May 14, 2025.
• CytoDyn also confirmed that it did not consult CBIZ on accounting principles or audit opinions prior to engaging them.
• Marcum has provided a letter to the SEC agreeing with the statements made by CytoDyn regarding their resignation.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the change in auditors is not inherently negative, the previous going concern warning from Marcum tempers any positive outlook.

Positives

• The transition to a new auditor appears to be smooth, with no reported disagreements on accounting or auditing matters.
• Marcum agrees with the statements made by CytoDyn regarding their resignation, as confirmed in their letter to the SEC.

Negatives

• Marcum's audit report for the fiscal year ended May 31, 2024, included an expression of substantial doubt about CytoDyn's ability to continue as a going concern.

Risks

• The change in auditors could potentially raise concerns among investors until CBIZ has completed its audit for the fiscal year ending May 31, 2025.
• The previously expressed doubt about CytoDyn's ability to continue as a going concern remains a significant risk factor.

Future Outlook

The document does not contain specific forward-looking statements regarding financial performance, but the engagement of a new auditor is a necessary step for future financial reporting.

Industry Context

Changes in auditing firms are not uncommon, especially following acquisitions or mergers within the accounting industry. Companies are required to disclose such changes to maintain transparency with investors.

Comparison to Industry Standards

• The process of changing auditors and disclosing the reasons for the change is standard practice and aligns with SEC regulations.
• Companies like General Electric, which replaced KPMG with Deloitte, and Tesla, which replaced HL&B with PricewaterhouseCoopers, have also undergone auditor changes, demonstrating that this is a normal part of corporate governance.
• The disclosure of no disagreements with the previous auditor is a positive sign, similar to what is often seen in other companies' auditor change announcements.

Stakeholder Impact

• Shareholders will want to monitor the audit results from CBIZ to gain confidence in the company's financial reporting.
• The change in auditors should not directly impact employees, customers, suppliers, or creditors.

Next Steps

• CBIZ will conduct an audit of CytoDyn's financial statements for the fiscal year ending May 31, 2025.
• CytoDyn will continue to work with CBIZ to ensure timely and accurate financial reporting.

Key Dates

Keywords

auditor, CBIZ, Marcum, accounting, CytoDyn, resignation, engagement